MCL1 and non-Hodgkin lymphoma: MYC and MCL1 mRNA downregulation has been described previously from the blood of patients treated with enitociclib during dose escalation and across many cancer indications including NHL and solid tumors using a qPCR clinical trial assay (28, 29).